Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, and Patrick J Mcenany. Catalyst Pharmaceuticals Inc. analyst estimates, including CPRX earnings per share estimates and analyst recommendations. Term Box: 4.205 USD to Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. in one year. Friday, July 13, 2018. Investors in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) had a good week, as its shares rose 6.3% to close at US$3.35 following the release of its quarterly results.It looks to have been a decent result overall - while revenue fell marginally short of analyst estimates at US$29m, statutory earnings beat expectations by a notable 327%, coming in at US$0.41 per share. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. 64.86% of the stock of Catalyst Pharmaceuticals is held by institutions. The company traded as low as $4.19 and last traded at $4.23. Catalyst Pharmaceuticals, Inc. has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Weaker technical forecast for Catalyst Pharmaceuticals as stock downgraded to Buy Candidate. From where I can buy PPJE? Catalyst Pharmaceuticals Inc market prognosis, Get Our PREMIUM Forecast Now, from ONLY $7.49! Short-term and long-term CPRX (Catalyst Pharmaceuticals Inc) The biopharmaceutical company earns $31.88 million in net income (profit) each year or $0.30 on an earnings per share basis. According to our analysis, this will not happen. CPRX stock price prediction, Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD). Top institutional shareholders include BlackRock Inc. (7.47%), Royce & Associates LP (2.32%), HealthInvest Partners AB (1.69%), Northern Trust Corp (1.21%), Bank of New York Mellon Corp (0.60%) and Russell Investments Group Ltd. (0.43%). What Is The Ownership Structure Like For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)? * Our share forecasts and predictions are made by, Catalyst Pharmaceuticals Inc Forecast. Yes. Our stock price predictions cover a period of 3 months. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 roxana — On average, they expect Catalyst Pharmaceuticals' stock price to reach $7.83 in the next year. See above. Catalyst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021. According to 5 analysts, the average rating for CPRX stock is "Buy." Help us improve our free forecast service with share! Catalyst Pharmaceuticals Inc technical analysis, In the past three months, Catalyst Pharmaceuticals insiders have sold more of their company's stock than they have bought. EPS Forecast Trend The chart above depicts the trend in analyst earnings per share (EPS) forecasts for Catalyst Pharmaceuticals, Inc. for the upcoming quarter. The official website for Catalyst Pharmaceuticals is www.catalystpharma.com. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Get daily stock ideas top-performing Wall Street analysts. Turning out attention to how the Catalyst Pharmaceuticals, Inc. stock has performed in comparison to its peers in the industry, here’s what we find: CPRX’s stock is -2.34% on the day and -11.41% in the past 12 months, while Zoetis Inc Cl A (ZTS) traded +0.75% in the last session and was positioned +23.38% up on its price 12 months ago. The company’s stock has been forecasted to trade at an average price of $7.4 over the course of the next 52 weeks, with a low of $5.5 and a high of $9. Catalyst Pharmaceuticals Inc stock has risen 80.37% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.InvestorsObserver’s proprietary ranking system, gives CPRX stock a score of 85 out of a possible 100.. That rank is influenced by a long-term technical score of 93. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Catalyst Pharmaceuticals Inc finance tips, 4.205 Catalyst Pharmaceuticals does not have a long track record of dividend growth. If you are looking for stocks with good return, Catalyst Pharmaceuticals Inc can be a profitable investment option. The CPRX stock price can go up Catalyst Pharmaceuticals has a market capitalization of $0.00 and generates $102.31 million in revenue each year. Catalyst Pharmaceuticals Stock Forecast NASDAQ:CPRX Price Target and Analyst Ratings. Beat Earnings Expectations And Analysts Now Have New Forecasts, Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q3 2020 Results - Earnings Call Transcript, Catalyst's (CPRX) Q3 Earnings Beat Estimates, Revenues Miss, Catalyst Pharmaceuticals EPS beats by $0.31, misses on revenue, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. CPRX expected stock price. Get the latest Catalyst Pharmaceuticals earnings report, revenues as well as upcoming CPRX earnings dates, historical financial reports, news, analysis & more. As of 2021 February 12, Friday … You can opt out at any time. CPRX prediction, Learn about financial terms, types of investments, trading strategies and more. Catalyst Pharmaceuticals Inc stock forecast, The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. Biotech player Todos Medical may soon rise to global recognition for its innovative testing solutions! Will CPRX price drop? MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. The forcast looks uncalculated - is there an error on this page? CPRX forecast, The CPRX ("CPRX" ) Catalyst Pharmaceuticals stock price target raised to $10 from $9 at Oppenheimer MarketWatch. Get short term trading ideas from the MarketBeat Idea Engine. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected]. To see all exchange delays and terms of use please see disclaimer. ), Catalyst Pharmaceuticals has received 290 “underperform” votes. Based on our forecasts, a long-term increase is expected, According to analyst projections, CPRX’s forecast low is $5.5 with $9 as the target high. Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. © American Consumer News, LLC dba MarketBeat® 2010-2021. Is CPRX stock price going to drop? Wednesday, March 20, 2019. Their forecasts range from $5.50 to $10.00. one Learn everything you need to know about successful options trading with this three-part video course. 2,305,299 shares changed hands during mid-day trading, an increase of 20% from the average session volume of 1,926,166 shares.